![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » TEVA ANNOUNCES OXYCONTIN LITIGATION DISMISSED; SETTLEMENT WITH PURDUE FINALIZED
TEVA ANNOUNCES OXYCONTIN LITIGATION DISMISSED; SETTLEMENT WITH PURDUE FINALIZED
Teva Pharmaceutical Industries Ltd. announced today that patent infringement litigation pertaining to Teva's generic version of Purdue's OxyContin (oxycodone HCl extended-release) Tablets has been dismissed by the United States District Court for the Southern District of New York pursuant to a settlement between Teva and The Purdue Frederick Company and certain of its affiliates. Yahoo Finance (http://biz.yahoo.com/bw/061016/20061016005649.html?.v=1)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct